Dana Pizzuti - Jun 24, 2024 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
Chief Med and Dev Officer
Signature
Marc Wilson, as attorney-in-fact
Stock symbol
CRNX
Transactions as of
Jun 24, 2024
Transactions value $
-$273,980
Form type
4
Date filed
6/25/2024, 05:03 PM
Previous filing
Apr 17, 2024
Next filing
Jul 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Options Exercise $160K +9.5K +34.19% $16.89 37.3K Jun 24, 2024 Direct
transaction CRNX Common Stock Sale -$434K -9.5K -25.48% $45.73 27.8K Jun 24, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Stock option (Right to Buy) Options Exercise $0 -9.5K -5.36% $0.00 168K Jun 24, 2024 Common Stock 9.5K $19.73 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $45.73 per share. The range of sales prices on the transaction date was $45.53 to $45.88 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
F2 The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.